Načítá se...
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
PURPOSE: Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials dem...
Uloženo v:
| Vydáno v: | Arch Gynecol Obstet |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7524817/ https://ncbi.nlm.nih.gov/pubmed/32833070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00404-020-05677-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|